钙敏感受体在帕金森病发病中的机制研究

陈 曦, 许 叶, 王 埮
海南医学院第一附属医院

摘要

目的：探讨钙敏感受体（CaSR）抑制剂（Calhex231）、CaSR激动剂（GdCl3）对PD炎症细胞模型发挥的作用。研究能否通过调控CaSR来影响的PD发生发展，为PD的研究提供了新的思路。方法:使用MPP+在人神经母细胞瘤（SH-SY5Y）细胞上制备PD炎症细胞模型，使用CCK8法检测不同浓度MPP+、Calhex231、GdCl3处理后对SH-SY5Y细胞增殖的影响，确定合适的药物实验浓度。分为空白对照组、MPP+组、Calhex231组、GdCl3组、MPP++Calhex231组、MPP++GdCl3组。采用Westernblot法检测各分组中CaSR、TH蛋白的表达水平和灰度分析；采用PCR法检测各分组中CaSR的mRNA表达水平；采用CCK8法分别检测各组细胞增殖的情况。结果:与空白对照组相比，使用250μmol/L的MPP+、25μmol/L的GdCl3处理后能明显抑制细胞增殖，使用3.13μmol/LCalhex231处理后可明显促进细胞增殖；与空白对照组比较，MPP+组、GdCl3组TH蛋白表达含量降低，Calhex231组TH蛋白表达含量升高；与MPP+组比较，MPP++Calhex231组TH蛋白表达含量升高，MPP++GdCl3组TH蛋白表达含量降低；与空白对照组相比，MPP+组、GdCl3组中CaSR的mRNA及CaSR蛋白表达上调，Calhex231组中CaSR的mRNA及CaSR蛋白表达下降；与MPP+组相比，MPP++Calhex231组中的CaSR的mRNA及CaSR蛋白表达下降、MPP++GdCl3组中CaSR的mRNA及CaSR蛋白表达上调；与空白对照组比较，MPP+、GdCl3组细胞增殖被抑制，Calhex231组细胞增殖被激活，与MPP+组相比，MPP++GdCl3组细胞增殖被抑制，MPP++Calhex231组细胞增殖被激活。结论CaSR抑制剂可促进PD炎症细胞模型增殖，CaSR调节剂可影响PD发生、发展过程。

关键词

钙敏感受体；帕金森病；神经母细胞瘤细胞；神经炎症；NLRP3

参考

[1]Gao MR, Wang M, Jia YY, et al. Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson's disease model[J]. Brain Res Bull, 2020,164:55-64.[2]任传忠,张敏,李玮,等.银杏内酯B对MPP~+诱导的帕金森病SH-SY5Y细胞模型中α-synuclein表达的影响[J].中国临床药理学杂志,2021,37(12):1551-1554.[3]Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism[J]. Lancet Neurol, 2006,5(4):355-363.[4]庞文渊,翟利杰,刘依琳,等.全球帕金森病综合治疗指南的分析[J].中国临床药理学杂志,2022,38(21):2638-2643.[5]Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy[J]. Science, 2019,366(6467):818-822.[6]张辉, 王运良. 帕金森病的发病机制及治疗进展[J].中国实用神经疾病杂志,2021,24(15):1371-1380.[7]Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology[J]. Clin Geriatr Med, 2020,36(1):1-12.[8]Giudice ML, Mihalik B, Dinnyés A, et al. The Nervous System Relevance of the Calcium Sensing Receptor in Health and Disease[J]. Molecules, 2019,24(14).[9]Ruat M, Molliver ME, Snowman AM, et al. Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals[J]. Proc Natl Acad Sci U S A, 1995,92(8):3161-3165.[10]Chen W, Bergsman JB, Wang X, et al. Presynaptic external calcium signaling involves the calcium-sensing receptor in neocortical nerve terminals[J]. PLoS One, 2010,5(1):e8563.[11]开伟华,丁彩娟,戴晨,等 l.钙敏感受体在大脑中作用研究进展[J].牡丹江医学院学报,2016,37(03):117-119.[12]Breen DP, Halliday GM, Lang AE. Gut-brain axis and the spread of α-synuclein pathology: Vagal highway or dead end?[J]. Mov Disord, 2019,34(3):307-316.[13]Masters CL, Kril JJ, Halliday GM, et al. Overview and recent advances in neuropathology. Part 2: Neurodegeneration[J]. Pathology, 2011,43(2):93-102.[14]Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease[J]. Nat Rev Neurol, 2019,15(10):565-581.[15]张鹏飞,于春泽,于建云, 等.NLRP3 炎性小体在中枢神经系统疾病中的作用研究进展[J].中国临床解剖学杂志,2022,40(01):113-116.[16]Surmeier DJ, Guzman JN, Sanchez J, et al. Physiological phenotype and vulnerability in Parkinson's disease[J]. Cold Spring Harb Perspect Med, 2012,2(7):a009290.[17]Dostert C, Pétrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica[J]. Science, 2008,320(5876):674-677.[18]Lee GS, Subramanian N, Kim AI, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP[J]. Nature, 2012,492(7427):123-127.